Thank you, Mr. Chair.
As you remember and as all of the members will recall, at the last meeting on Thursday, I had put forward what's called the old amendment Lib-1. It had created a certain amount of confusion, not only with some of the experts, but also with me.
Just to summarize, my intention had been to reinstate schedule 1 of medications that are in the Patent Act, to bring it into Bill C-393, and also to establish that any medications that would be used under CAMR had to have Health Canada approval.
Well, I didn't realize there were a number of other definitions that had been removed in Bill C-393 that were really required to be reinstated because they were called up, notably the definition of “patented product”, “WTO”, and things like that. It's also to make sure, as I said, that medications allowed under CAMR would meet Health Canada approval.
I got together with the legislative assistant on Thursday afternoon, which gave rise to a number of alternate amendments called Lib-1.1 through to Lib-1.6. That's really the new part of it, what is being introduced here this morning, which I believe will rectify the problems that were identified last Thursday afternoon.
Thank you, Mr. Chair.